home / stock / prnb / prnb news

PRNB News and Press, Principia Biopharma Inc. From 03/04/19

Stock Information
Company Name: Principia Biopharma Inc.
Stock Symbol: PRNB
Market: NASDAQ
Website: principiabio.com
Menu
PRNB PRNB Quote PRNB Short PRNB News PRNB Articles PRNB Message Board
Get PRNB Alerts

News, Short Squeeze, Breakout and More Instantly...
PRNB - Principia Bio's lead candidate successful in mid-stage pemphigus study

Thinly traded Principia Biopharma ( PRNB +1.1% ) is up, albeit on turnover of only 5K shares, following its announcement of positive results from an open-label Phase 2 clinical trial evaluating its lead candidate, Orphan Drug-tagged PRN1008, in pemphigus patients. The data were present...
PRNB - Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation

-- Reached primary endpoint of Control of Disease Activity at four weeks in 54 percent of patients on low dose corticosteroids -- -- Median Anti-DSG antibodies reduced by up to 65 percent with 12 weeks of treatment --  -- Complete Response rate of 25 percent with 12 weeks of treat...

PRNB - Principia Bio up 3% on positive PRN2246 data

Thinly traded Principia Biopharma ( PRNB +3.4% ) is up on below-average volume on the heels of Phase 1 data on multiple sclerosis candidate PRN2246, a Bruton's tyrosine kinase (BTK) inhibitor that crosses the blood-brain barrier. The results were presented at ACTRIMS in Dallas, TX. Mor...

PRNB - Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019

-- Orally administered PRN2246 achieved full BTK occupancy in peripheral blood -- -- PRN2246 exhibited blood-brain barrier permeability and CNS exposure -- -- Sanofi to lead Phase 2 development for people with Multiple Sclerosis -- SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE ...
PRNB - Principia Biopharma Announces the Acceptance of Data from Phase 2 Pemphigus Vulgaris Trial as a Late-Breaking Presentation at 2019 American Academy of Dermatology Meeting

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced tha...

PRNB - Principia Biopharma to Present at 8th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced tha...

PRNB - Principia Biopharma Appoints John W. Smither to Board of Directors

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the...
Previous 10 Next 10